Galderma is a pure-play dermatology company headquartered in Zug, Switzerland, and listed on the SIX Swiss Exchange under the ticker GALD. Present in approximately 90 countries, the company operates an integrated platform across three categories of the dermatology market: Injectable Aesthetics (Restylane, Sculptra, Dysport), Dermatological Skincare (Cetaphil, Alastin), and Therapeutic Dermatology (Nemluvio, Differin, Aklief, Soolantra).
The portfolio combines premium physician-dispensed and professional-administered products with widely distributed consumer skincare, spanning prescription medicines, medical devices such as dermal fillers, and over-the-counter brands. Founded in 1981 and carved out of Nestlé in 2019, Galderma describes itself as the only scaled company dedicated solely to skin, serving both healthcare professionals and consumers across the full spectrum of dermatology.
Galderma operates in what it describes as a fast-growing dermatology market and entered the second half of 2026 with raised ambitions: after record first-half net sales of $3.134 billion USD, it raised full-year 2026 net sales growth guidance to 19-21% at constant currency while confirming a Core EBITDA margin of approximately 26%. Growth is broad-based across geographies, with the United States, its largest market, contributing more than 40% of 2025 net sales, receiving stepped-up investment including a new Miami headquarters and over 650 million USD of manufacturing spending through 2030.
Innovation-led products underpin the outlook: Nemluvio generated 433 million USD in first-half 2026 net sales as a newly launched biologic, and the next-generation neuromodulator Relfydess continues to ramp with approvals in 33 international markets, while the Therapeutic Dermatology category grew 67.9% year-on-year in the first half. Management frames the strategic goal as closing the gap with Allergan Aesthetics (AbbVie) in injectables market share in the U.S., the category's largest market.
Galderma's principal differentiation is its exclusive focus on dermatology at global scale: management describes the company as the only scaled pure-play dermatology company, with leadership positions in each of its three categories and an integrated strategy linking injectable aesthetics, skincare, and therapeutic products rather than competing in a single segment. Its flagship brands, including Cetaphil, Restylane, Sculptra, and Nemluvio, are category leaders, and the company states it outperformed the market in every product category in the first half of 2026.
The company pairs its brand portfolio with science-based differentiation and professional-channel reach: proprietary technologies such as NASHA hyaluronic-acid gels and Alastin's TriHex peptide platform, a first-in-class IL-31 inhibitor in Nemluvio, a large professional training network, and dedicated manufacturing scale including a commitment to invest more than 650 million USD in U.S. manufacturing through 2030. The United States, its largest market, generated more than 40% of 2025 global net sales.
Galderma pursues a premium-brand pricing strategy across its three dermatology categories, positioning its injectable fillers, neuromodulators, biologics, and dermatologist-recommended skincare at the upper end of their respective markets. Its revenue mix spans higher-priced physician-administered injectables and prescription biologics alongside mass-market consumer skincare such as Cetaphil, giving it exposure to both premium professional channels and broad retail distribution.
The company states that its growth is primarily volume-driven and complemented by favorable product mix, and it manages the portfolio for margin expansion as well as share: in the first half of 2026 it reported Core EBITDA of 802 million USD, a 25.6% margin that expanded 328 basis points at constant currency, while raising full-year guidance. This indicates a strategy of scaling premium brands and shifting mix toward higher-value innovation, including its next-generation neuromodulator Relfydess and the Nemluvio biologic, rather than competing on price.
